$NBIX
NEUROCRINE BIOSCIENCES INC Stock $nbix

$nbix Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000091447524000181 Filed on August 01, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$622.1M	$590.2M
YoY Change	24.72%	30.37%
Cost Of Revenue	$8.000M	$9.200M
YoY Change	-28.57%	-20.0%
Gross Profit	$614.1M	$581.0M
YoY Change	25.94%	31.69%
Gross Profit Margin	98.71%	98.44%
Selling, General & Admin	$234.3M	$242.0M
YoY Change	14.74%	9.11%
% of Gross Profit	38.15%	41.65%
Research & Development	$195.0M	$191.1M
YoY Change	37.13%	31.07%
% of Gross Profit	31.75%	32.89%
Depreciation & Amortization	$6.500M	$7.300M
YoY Change	18.18%	43.14%
% of Gross Profit	1.06%	1.26%
Operating Expenses	$429.3M	$433.1M
YoY Change	23.93%	17.82%
Operating Profit	$183.8M	$145.4M
YoY Change	30.17%	97.55%
Interest Expense	$6.500M	-$46.80M
YoY Change	490.91%	-197.5%
% of Operating Profit	3.54%	-32.19%
Other Income/Expense, Net	$6.500M	-$46.80M
YoY Change	-125.39%	-197.5%
Pretax Income	$190.3M	$98.60M
YoY Change	64.62%	-18.91%
Income Tax	$60.50M	$33.60M
% Of Pretax Income	31.79%	34.08%
Net Earnings	$129.8M	$65.00M
YoY Change	56.2%	-31.94%
Net Earnings / Revenue	20.86%	11.01%
Basic Earnings Per Share	$1.28	$0.64
Diluted Earnings Per Share	$1.24	$0.63
COMMON SHARES
Basic Shares Outstanding	101.0M shares	100.6M shares
Diluted Shares Outstanding	104.3M shares	103.9M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.228B	$1.039B
YoY Change	12.14%	6.37%
Cash & Equivalents	$349.1M	$139.7M
Short-Term Investments	$878.9M	$899.2M
Other Short-Term Assets	$121.7M	$120.2M
YoY Change	12.48%	19.48%
Inventory	$45.80M	$42.50M
Prepaid Expenses
Receivables	$481.1M	$468.2M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.877B	$1.670B
YoY Change	13.74%	11.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$80.00M	$80.10M
YoY Change	16.28%	-46.28%
Goodwill	$6.100M	$5.700M
YoY Change	10.91%	0.0%
Intangibles	$34.50M	$33.50M
YoY Change	-1.15%	-9.21%
Long-Term Investments	$770.6M	$781.4M
YoY Change	31.17%	51.55%
Other Assets	$61.60M	$57.80M
YoY Change	42.92%	-86.07%
Total Long-Term Assets	$1.658B	$1.635B
YoY Change	38.4%	46.46%
TOTAL ASSETS
Total Short-Term Assets	$1.877B	$1.670B
Total Long-Term Assets	$1.658B	$1.635B
Total Assets	$3.535B	$3.305B
YoY Change	24.11%	26.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$277.3M	$264.0M
YoY Change	-29.78%	-32.58%
Accrued Expenses	$150.2M	$129.9M
YoY Change	19.3%	633.9%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Total Short-Term Liabilities	$429.7M	$398.5M
YoY Change	-37.87%	-31.59%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$135.0M	$141.1M
YoY Change	96.79%	-20.55%
Total Long-Term Liabilities	$135.0M	$141.1M
YoY Change	96.79%	-20.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$429.7M	$398.5M
Total Long-Term Liabilities	$135.0M	$141.1M
Total Liabilities	$816.1M	$795.8M
YoY Change	-3.55%	4.7%
SHAREHOLDERS EQUITY
Retained Earnings	$81.10M	-$48.70M
YoY Change	-126.61%	-87.45%
Common Stock	$2.623B	$2.555B
YoY Change	13.63%	13.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.719B	$2.509B
YoY Change
Total Liabilities & Shareholders Equity	$3.535B	$3.305B
YoY Change	24.11%	26.48%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	$129.8M	$65.00M
YoY Change	56.2%	-31.94%
Depreciation, Depletion And Amortization	$6.500M	$7.300M
YoY Change	18.18%	43.14%
Cash From Operating Activities	$158.0M	$64.60M
YoY Change	-25.47%	-64.03%
INVESTING ACTIVITIES
Capital Expenditures	$8.100M	$11.60M
YoY Change	6.58%	70.59%
Acquisitions
YoY Change
Other Investing Activities	$32.80M	-$16.60M
YoY Change	-136.57%	-86.06%
Cash From Investing Activities	$24.70M	-$28.20M
YoY Change	-125.39%	-77.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	26.40M	-293.0M
YoY Change	40.43%	-10203.45%
NET CHANGE
Cash From Operating Activities	158.0M	64.60M
Cash From Investing Activities	24.70M	-28.20M
Cash From Financing Activities	26.40M	-293.0M
Net Change In Cash	209.1M	-256.6M
YoY Change	56.63%	-553.36%
FREE CASH FLOW
Cash From Operating Activities	$158.0M	$64.60M
Capital Expenditures	$8.100M	$11.60M
Free Cash Flow	$149.9M	$53.00M
YoY Change	-26.66%	-69.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	26100000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	24700000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-600000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	65000000.0	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	95500000	usd
	us-gaap	Net Income Loss NetIncomeLoss	108400000	usd
	us-gaap	Net Income Loss NetIncomeLoss	18900000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-100000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-900000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	400000	usd
	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	-2100000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-900000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	700000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-4100000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	4700000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	64200000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	97100000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	103900000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	25700000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.98
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.08
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.63
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.95
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.19
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100800000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97600000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100300000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97400000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103900000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100200000	shares
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	2386100000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	65000000.0	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-800000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	43100000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	15800000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	2509200000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	1684500000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1600000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	68500000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2900000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1853000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	108400000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-4500000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	87600000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	85700000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	2509200000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	1707800000	usd
	us-gaap	Net Income Loss NetIncomeLoss	18900000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	108400000	usd
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11100000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	1853000000	usd
	us-gaap	Net Income Loss NetIncomeLoss	108400000	usd
	us-gaap	Net Income Loss NetIncomeLoss	18900000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	87600000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	108400000	usd
	nbix	Charges Associated With Convertible Senior Notes ChargesAssociatedWithConvertibleSeniorNotes	138400000	usd
	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	14000000.0	usd
	us-gaap	Impairment Of Leasehold ImpairmentOfLeasehold	0	usd
	us-gaap	Depreciation Depreciation	11700000	usd
	us-gaap	Depreciation Depreciation	8300000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	14100000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	6000000.0	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1800000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1800000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-18300000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	39500000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-56900000	usd
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-73100000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	3600000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	-300000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	28900000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	37500000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-111400000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-102500000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	259100000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	270700000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4200000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3400000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-78100000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	22900000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	6700000	usd
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-47100000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	194900000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	54400000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	511800000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	451400000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	408600000	usd
	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	31300000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22800000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-83200000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	85700000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	308800000	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11100000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-111400000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-102500000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	259100000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	270700000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3300000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	800000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	9000000.0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1800000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1600000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1900000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	92800000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	3400000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	147700000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	168200000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3300000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	800000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	9000000.0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1800000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1600000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	900800000	usd
CY2024Q2	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent	100000	usd
CY2024Q2	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent	1700000	usd
CY2024Q2	nbix	Debt Securities Available For Sale Fair Value Current DebtSecuritiesAvailableForSaleFairValueCurrent	899200000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Current DebtSecuritiesAvailableForSaleAmortizedCostCurrent	781700000	usd
CY2023Q4	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent	300000	usd
CY2023Q4	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent	1500000	usd
CY2023Q4	nbix	Debt Securities Available For Sale Fair Value Current DebtSecuritiesAvailableForSaleFairValueCurrent	780500000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	639800000	usd
CY2024Q2	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	400000	usd
CY2024Q2	nbix	Debt Securities Available For Sale Fair Value Noncurrent DebtSecuritiesAvailableForSaleFairValueNoncurrent	637800000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Amortized Cost Noncurrent DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent	684600000	usd
CY2023Q4	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent	3400000	usd
CY2023Q4	nbix	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent	500000	usd
CY2023Q4	nbix	Debt Securities Available For Sale Fair Value Noncurrent DebtSecuritiesAvailableForSaleFairValueNoncurrent	687500000	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	12600000	usd
CY2023Q4	us-gaap	Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss	11200000	usd
	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	usd
	us-gaap	Debt Securities Available For Sale Accrued Interest Writeoff DebtSecuritiesAvailableForSaleAccruedInterestWriteoff	0	usd
CY2024Q2	us-gaap	Investments Investments	1828300000	usd
CY2023Q4	us-gaap	Investments Investments	1889000000	usd
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	21300000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	21500000	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	12000000.0	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	9700000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	10400000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	12300000	usd
CY2024Q2	us-gaap	Inventory Gross InventoryGross	43700000	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	43500000	usd
CY2024Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1200000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	5200000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	42500000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	38300000	usd
CY2024Q2	us-gaap	Investments Investments	1828300000	usd
CY2023Q4	us-gaap	Investments Investments	1889000000	usd
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	21300000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	21500000	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	12000000.0	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	9700000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	10400000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	12300000	usd
CY2024Q2	us-gaap	Inventory Gross InventoryGross	43700000	usd
CY2023Q4	us-gaap	Inventory Gross InventoryGross	43500000	usd
CY2024Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1200000	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	5200000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	42500000	usd
CY2024Q2	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	121700000	usd
CY2023Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	139300000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	59800000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	86200000	usd
CY2024Q2	nbix	Accrued Branded Prescription Drug Fee AccruedBrandedPrescriptionDrugFee	35300000	usd
CY2023Q4	nbix	Accrued Branded Prescription Drug Fee AccruedBrandedPrescriptionDrugFee	45700000	usd
CY2024Q2	nbix	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	34700000	usd
CY2023Q4	nbix	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	44300000	usd
CY2024Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	107200000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	133300000	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	358500000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	448800000	usd
CY2024Q2	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	121700000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	86200000	usd
CY2024Q2	nbix	Accrued Branded Prescription Drug Fee AccruedBrandedPrescriptionDrugFee	35300000	usd
CY2023Q4	nbix	Accrued Branded Prescription Drug Fee AccruedBrandedPrescriptionDrugFee	45700000	usd
CY2024Q2	nbix	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	34700000	usd
CY2023Q4	nbix	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	44300000	usd
CY2024Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	107200000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	133300000	usd
CY2024Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	358500000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	448800000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	96000000.0	usd
CY2024Q2	nbix	Prescription Drug Fee Noncurrent PrescriptionDrugFeeNoncurrent	30100000	usd
CY2023Q4	nbix	Prescription Drug Fee Noncurrent PrescriptionDrugFeeNoncurrent	10300000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	141100000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	106300000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	139700000	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	8000000.0	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	147700000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	5800000	usd
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-100000	usd
CY2024Q2	us-gaap	Goodwill Goodwill	5700000	usd
CY2024Q2	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	111000000.0	usd
CY2023Q4	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	96000000.0	usd
CY2024Q2	nbix	Prescription Drug Fee Noncurrent PrescriptionDrugFeeNoncurrent	30100000	usd
CY2023Q4	nbix	Prescription Drug Fee Noncurrent PrescriptionDrugFeeNoncurrent	10300000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	141100000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	106300000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	139700000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	160200000	usd
CY2024Q2	us-gaap	Restricted Cash RestrictedCash	8000000.0	usd
CY2023Q2	us-gaap	Restricted Cash RestrictedCash	8000000.0	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	147700000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	168200000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	5800000	usd
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-100000	usd
CY2024Q2	us-gaap	Goodwill Goodwill	5700000	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	33500000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	35500000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1800000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3600000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3600000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3600000	usd
CY2024Q2	nbix	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	13600000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	8200000	usd
	us-gaap	Sublease Income SubleaseIncome	800000	usd
	us-gaap	Sublease Income SubleaseIncome	0	usd
	nbix	Operating Leases Rent Expense Net Sublease Income OperatingLeasesRentExpenseNetSubleaseIncome	17800000	usd
	nbix	Operating Leases Rent Expense Net Sublease Income OperatingLeasesRentExpenseNetSubleaseIncome	8200000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	15000000.0	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.050
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.054
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	18000000.0	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	35500000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1800000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3600000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3600000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3600000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3600000	usd
CY2024Q2	nbix	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	13600000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	18600000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	8200000	usd
	us-gaap	Sublease Income SubleaseIncome	800000	usd
	us-gaap	Sublease Income SubleaseIncome	0	usd
	nbix	Operating Leases Rent Expense Net Sublease Income OperatingLeasesRentExpenseNetSubleaseIncome	17800000	usd
	nbix	Operating Leases Rent Expense Net Sublease Income OperatingLeasesRentExpenseNetSubleaseIncome	8200000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	15000000.0	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	8800000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P10Y6M
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y4M24D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.050
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	1000000.0	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	35400000	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	2700000	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	2700000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	35800000	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	2700000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	36600000	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	2700000	usd
CY2024Q2	nbix	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	220300000	usd
CY2024Q2	nbix	Lessor Operating Lease Payment To Be Received After Year Four LessorOperatingLeasePaymentToBeReceivedAfterYearFour	7000000.0	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	1000000.0	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	35400000	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	2700000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	34900000	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	2700000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	35800000	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	2700000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	36600000	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	2700000	usd
CY2024Q2	nbix	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	220300000	usd
CY2024Q2	nbix	Lessor Operating Lease Payment To Be Received After Year Four LessorOperatingLeasePaymentToBeReceivedAfterYearFour	7000000.0	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	381000000.0	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	18800000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	89400000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	291600000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	35400000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	256200000	usd
CY2024Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On First Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary	5600000	usd
CY2024Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On Second Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary	22600000	usd
CY2024Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On Third Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary	23300000	usd
CY2024Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On Fourth Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary	24000000.0	usd
CY2024Q2	nbix	Unrecorded Unconditional Purchase Obligation To Be Paid After Year Four UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour	214400000	usd
CY2024Q2	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	14000000.0	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	126600000	usd
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-9600000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2200000	usd
	nbix	Charges Associated With Convertible Senior Notes ChargesAssociatedWithConvertibleSeniorNotes	138400000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	381000000.0	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	18800000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	89400000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	35400000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	256200000	usd
CY2024Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On First Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary	5600000	usd
CY2024Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On Second Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnSecondAnniversary	22600000	usd
CY2024Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On Third Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnThirdAnniversary	23300000	usd
CY2024Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On Fourth Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnFourthAnniversary	24000000.0	usd
CY2024Q2	nbix	Unrecorded Unconditional Purchase Obligation To Be Paid After Year Four UnrecordedUnconditionalPurchaseObligationToBePaidAfterYearFour	214400000	usd
CY2024Q2	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	14000000.0	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	126600000	usd
	us-gaap	Embedded Derivative Gain Loss On Embedded Derivative Net EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet	-9600000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2200000	usd
	nbix	Charges Associated With Convertible Senior Notes ChargesAssociatedWithConvertibleSeniorNotes	138400000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	65000000.0	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	65000000.0	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	95500000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	95500000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	108400000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	108400000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	18900000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	18900000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	65000000.0	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	65000000.0	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	95500000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	95500000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	108400000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	108400000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	18900000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	18900000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100800000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97600000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100300000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97400000	shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3100000	shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2600000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3500000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2900000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103900000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100200000	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.64
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.98
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.19
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.63
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.95
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.19
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2300000	shares
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6700000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2000000.0	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5600000	shares
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100800000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97600000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100300000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97400000	shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3100000	shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2600000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3500000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2900000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103900000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100200000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103800000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100300000	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.64
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.98
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.19
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.63
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.95
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.04
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.19
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2300000	shares
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6700000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5600000	shares
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
nbix-20240630_htm.xml	Edgar Link	completed
0000914475-24-000181-index-headers.html	Edgar Link	pending
0000914475-24-000181-index.html	Edgar Link	pending
0000914475-24-000181.txt	Edgar Link	pending
0000914475-24-000181-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nbix-20240630.htm	Edgar Link	pending
nbix-20240630.xsd	Edgar Link	pending
nbix-20240630_g1.jpg	Edgar Link	pending
q2-2024xexhibit101.htm	Edgar Link	pending
q2-2024xexhibit101001.jpg	Edgar Link	pending
q2-2024xexhibit101002.jpg	Edgar Link	pending
q2-2024xexhibit101003.jpg	Edgar Link	pending
q2-2024xexhibit101004.jpg	Edgar Link	pending
q2-2024xexhibit101005.jpg	Edgar Link	pending
q2-2024xexhibit101006.jpg	Edgar Link	pending
q2-2024xexhibit101007.jpg	Edgar Link	pending
q2-2024xexhibit101008.jpg	Edgar Link	pending
q2-2024xexhibit101009.jpg	Edgar Link	pending
q2-2024xexhibit102.htm	Edgar Link	pending
q2-2024xexhibit102001.jpg	Edgar Link	pending
q2-2024xexhibit311.htm	Edgar Link	pending
q2-2024xexhibit312.htm	Edgar Link	pending
q2-2024xexhibit32.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
nbix-20240630_cal.xml	Edgar Link	unprocessable
nbix-20240630_def.xml	Edgar Link	unprocessable
nbix-20240630_lab.xml	Edgar Link	unprocessable
nbix-20240630_pre.xml	Edgar Link	unprocessable
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NBIX
NEUROCRINE BIOSCIENCES INC Stock $nbix

2024 Q3 Form 10-Q Financial Statement

#000091447524000181 Filed on August 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBIX NEUROCRINE BIOSCIENCES INC Stock $nbix

2024 Q3 Form 10-Q Financial Statement

#000091447524000181 Filed on August 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NBIX
NEUROCRINE BIOSCIENCES INC Stock $nbix